Related Experiment Video
Updated: Mar 29, 2026
Retroviral Transduction of T-cell Receptors in Mouse T-cells
Published on: October 22, 2010
T-Cell Receptor-Transduced T Cells: Clinical Experience
1From the National Institutes of Health, National Cancer Institute, Surgery Branch, Bethesda, MD.
Abstract:
The large number of T-cell epitopes that have been found to be processed and presented on human tumors, now numbering in the hundreds, provides a rich source of targets for therapeutic interventions aimed at inducing durable tumor regression. Vaccination strategies aimed at inducing responses to these antigens have been largely ineffective, and it has been challenging to generate large numbers of T cells with the functional capacity to mediate durable tumor regressions in adoptive immunotherapy strategies in patients who have common epithelial malignancies. The ability to generate T-cell receptors that recognize shared as well as unique antigens expressed in a wide variety of common tumor types that include lung, breast, ovarian, gastrointestinal, urothelial, and genitourinary cancers provides an opportunity to develop widely applicable therapies based on the adoptive transfer of autologous T cells transduced with those receptors.
Insights
Hundreds of T-cell epitopes in human tumors offer therapeutic targets. Engineering T-cell receptors for adoptive immunotherapy shows promise for treating common cancers like lung and breast cancer.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Numerous T-cell epitopes are presented on human tumors, offering potential targets for cancer therapies.
- Current vaccination strategies targeting these epitopes have shown limited efficacy.
- Generating sufficient functional T cells for adoptive immunotherapy in epithelial malignancies remains a challenge.
Purpose of the Study:
- To explore the potential of T-cell receptors (TCRs) targeting shared and unique tumor antigens.
- To develop broadly applicable adoptive cell therapies for common epithelial cancers.
Main Methods:
- Identification and characterization of T-cell epitopes presented on human tumors.
- Engineering of T-cell receptors (TCRs) capable of recognizing these tumor-associated antigens.
- Transduction of autologous T cells with engineered TCRs for adoptive transfer.
Main Results:
- The study highlights a large repertoire of T-cell epitopes across various cancers.
- The engineered TCRs demonstrate the potential to recognize diverse tumor antigens.
- This approach enables the generation of T cells for adoptive immunotherapy.
Conclusions:
- Engineered T-cell receptors offer a promising strategy for developing widely applicable cancer immunotherapies.
- Adoptive transfer of autologous T cells engineered with specific TCRs can target a range of common epithelial cancers.
- This approach holds potential for inducing durable tumor regression.
More Related Videos
11:21Streamlined Single Cell TCR Isolation and Generation of Retroviral Vectors for In Vitro and In Vivo Expression of Human TCRs
Published on: September 10, 2017
08:48Generating De Novo Antigen-specific Human T Cell Receptors by Retroviral Transduction of Centric Hemichain
Published on: October 25, 2016
Related Concept Videos
01:22T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:27Tumor Immunotherapy
01:40Cell-mediated Immune Responses